Cystic fibrosis liver disease: A condition in need of structured transition and continuity of care

Can Liver J. 2019 Aug 27;2(3):71-83. doi: 10.3138/canlivj-2018-0019. eCollection 2019 Summer.

Abstract

Liver disease affects one-third of patients with cystic fibrosis (CF) and it is one of the major causes of morbidity and mortality in these patients. Historically considered a disease of childhood, its impact is now seen more often in adulthood. The heterogeneous pattern of CF liver disease and its rapid progression to cirrhosis remain a diagnostic challenge and new questions pertaining to the nature of liver involvement have recently been raised. Non-invasive measures to stratify the severity of liver involvement are increasingly used to predict clinical outcomes. A single treatment, ursodeoxycholic acid, has been used to slow progression of liver disease while recent advances in the field of CF treatments are promising. Management of portal hypertension remains challenging but outcomes after liver transplantation are encouraging. While many questions remain unanswered, a growing number of CF patients reach adulthood and will require care for CF liver disease.

Keywords: biliary cirrhosis; cystic fibrosis; cystic fibrosis liver disease; non-invasive diagnosis; portal hypertension.

Publication types

  • Review